
Biotech company Orphazyme’s has commenced in-court restructuring proceedings, a press release announces on Friday.
The company’s creditors have been summoned for a meeting on April 17, when they will be presented the plans, but won’t have their hands on the statutory restructuring plan until March 31.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app